Inflammasome Therapeutics
PrivateLast Round
Seed Round
May 4, 2026
Total Funding Raised
$3.22M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Inflammasome Therapeutics is a biotechnology company that develops therapies for prevalent, degenerative diseases such as Alzheimer's, multiple sclerosis, and macular degeneration by preventing aberrant inflammasome activation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inflammasome Therapeutics Comparables
Compare Inflammasome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NodThera | 89% | |
| Halia Therapeutics | 88% | |
| IFM Therapeutics | 87% |
Inflammasome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | May 4, 2026 | ||||
| Grant | May 1, 2025 | ||||
| Seed Round | Jan 26, 2024 | ||||
| Grant | Aug 9, 2021 | ||||
| Grant | Sep 16, 2020 | ||||
Strategic | Sep 20, 2019 |
Inflammasome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boehringer Ingelheim | Strategic |
| Gates Foundation | Grant |
| Bill & Melinda Gates Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 57% QoQ from 7 to 11 employees.
- May 27, 2026
Grew 125% QoQ, from 4 to 9 employees.
Inflammasome Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Inflammasome Therapeutics's valuation, stock price, and market status.
Is Inflammasome Therapeutics a public or private company?
Inflammasome Therapeutics is a private company.
What is the current stock price of Inflammasome Therapeutics?
Inflammasome Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Inflammasome Therapeutics worth (valuation)?
Valuation information for Inflammasome Therapeutics is not publicly available.
Can I buy Inflammasome Therapeutics stock?
Inflammasome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Inflammasome Therapeutics's last funding round?
Inflammasome Therapeutics's most recent funding round was Seed Round on May 4, 2026.
Who are the main investors in Inflammasome Therapeutics?
Key investors in Inflammasome Therapeutics include Boehringer Ingelheim.
Will Inflammasome Therapeutics IPO soon?
No public IPO plans have been announced for Inflammasome Therapeutics.
How can I track Inflammasome Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Inflammasome Therapeutics's secondary market activity and sign up for updates.